Indications

It’s indicated for active immunization against EV71-associated hand, foot, mouth disease.

Highlights

1. The World’s first EV 71 vaccine, launched in 2015.

2. Complete clinical phase I、 II、 III report

3. Clinical trial result was published in The New England Journal of Medicine in 2014

Specification

0.5 ml/single dose (vial or pre-filled syringe)

Dosage form

Liquid

Route of Administration 

Intramuscular injection

Shelf life

24 Months